Reaction

Vulvovaginal Pain reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,719 reports · 40 co-occurring drugs

As of the last recalculation, Vulvovaginal Pain appears in 4,719 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is MICONAZOLE NITRATE (PRR 641.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Miconazole Nitrate	1,001	641.8	725.3
Estradiol	450	25.3	25.4
Etonogestrel And Ethinyl Estradiol	102	20.7	20.8
Copper	177	18.8	18.9
Conjugated Estrogens	235	18.7	18.7
Ado-Trastuzumab Emtansine	35	18.4	18.5
Estrogens, Conjugated	234	18.2	18.3
Estradiol Gel 0.1%	102	10.2	10.2
Estradiol Transdermal	102	10.1	10.2
Levonorgestrel	403	9.6	9.6
Drs. Clotrimazole	23	8.8	8.8
Family Wellness Clotrimazole	23	8.8	8.8
Clotrimazole Topical	23	8.8	8.8
Clotrimazole	23	8.3	8.3
Human Immunoglobulin G	27	5.8	5.8
Pertuzumab	30	4.9	4.9
Heparin Sodium	15	4.8	4.8
Clindamycin Phosphate	32	4.2	4.3
Thyroid, Porcine	10	4.1	4.1
Naproxen Sodium Tablet, Coated	11	3.6	3.6
Naproxen Sodium, Coated Tablets	11	3.6	3.6
Naproxen Sodium 220Mg	11	3.6	3.6
Metronidazole	51	3.5	3.6
Etonogestrel	37	3.4	3.4
Tretinoin	6	3.3	3.3
Progesterone	16	3.1	3.1
Tramadol Hydrochloride	26	3.1	3.1
Oxybutynin	19	2.9	2.9
Mirabegron	25	2.9	2.9
Empagliflozin	40	2.6	2.6
Leuprolide Acetate	43	2.5	2.5
Dapagliflozin	17	2.4	2.4
Trastuzumab	32	2.1	2.1
Fesoterodine Fumarate	5	2.0	2.0
Linaclotide	12	2.0	2.0
Vilazodone Hydrochloride	4	1.9	1.9
Canagliflozin	12	1.8	1.8
Medroxyprogesterone Acetate	19	1.7	1.7
Vibegron	3	1.7	1.7
Drospirenone And Ethinyl Estradiol	16	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.